Inhibition of factor Xa by a peptidyl-alpha-ketothiazole involves two steps. Evidence for a stabilizing conformational change.
Recently, peptidylketothiazoles have been shown to be potent inhibitors of proteases, but the details of the interaction have not yet been studied. In the work presented here, the interaction of factor Xa, a coagulation protease, with the transition state inhibitor BnSO(2)-D-Arg-Gly-Arg-ketothiazole (C921-78) is characterized. C921-78 is a tight and selective inhibitor of the coagulation protease factor Xa (K(d) = 14 pM). The hydrolytic activity of factor Xa was inhibited by C921-78 in a time-dependent manner. The rate-limiting step of the bimolecular combination of inhibitor and enzyme was competitive with the substrate. Conversely, the inhibitor could be displaced from the active site of the enzyme after exposure of the preformed complex to an excess of substrate or to the active site inhibitor dansyl-Glu-Gly-Arg-chloromethyl ketone (DEGR-CMK) in a slow reaction. The formation of the C921-78-factor Xa complex resulted in a 60% increase in the magnitude of the fluorescence emission spectrum. Rapid mixing of the enzyme and inhibitor produces a monophasic fluorescence increase, compatible with spectral transition in a single step. The rate constant for this reaction increased hyperbolically with the concentration of C921-78, but the amplitude remained constant. These results are consistent with the initial formation of an enzyme-inhibitor complex (EI), followed by a unimolecular conversion of EI to EI linked to a spectral transition. The rate constants of the isomerization provide an estimate of 300000-fold stabilization. Thus, the inhibition of factor Xa by C921-78 follows a mechanism similar to that described classically for slow tight binding inhibitors. However, the two steps of the reaction cannot be kinetically separated by the rapid equilibrium assumption, and therefore, the formation of EI is partially rate-limiting, too. The driving energy for the unusually fast isomerization step may result from the highly favorable interactions of the inhibitor in the primary binding site.
Betz
A
A
Cor Therapeutics, Inc., South San Francisco, California 94080, USA. abetz@corr.com
Wong
P W
PW
Sinha
U
U
D000595:Amino Acid Sequence; D020134:Catalytic Domain; D004795:Enzyme Stability / Q000187:drug effects; D015951:Factor Xa / Q000737:chemistry; D065427:Factor Xa Inhibitors; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology*; D011487:Protein Conformation / Q000187:drug effects; D015842:Serine Proteinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D013050:Spectrometry, Fluorescence; D013844:Thiazoles / Q000737:chemistry / Q000494:pharmacology*; D013925:Thromboplastin / Q000037:antagonists & inhibitors
C400786:BnSO(2)-D-Arg-Gly-Arg-ketothiazole; D065427:Factor Xa Inhibitors; D009842:Oligopeptides; D015842:Serine Proteinase Inhibitors; D013844:Thiazoles; D013925:Thromboplastin; D015951:Factor Xa